Title:
Handbook of therapeutic biomarkers in cancer
Publication Information:
Singapore : Pan Stanford Publishing, 2013
Physical Description:
xvi, 499 pages : illustrations ; 24 cm.
ISBN:
9789814364652
Available:*
Library | Item Barcode | Call Number | Material Type | Item Category 1 | Status |
|---|---|---|---|---|---|
Searching... | 32050000000766 | RC270.8 H36 2013 | Open Access Book | Handbook | Searching... |
On Order
Summary
Summary
In this volume, a team of internationally recognized experts provide an in-depth description of therapeutic biomarkers across a broad area of cancer research and oncology. With a wealth of information to specific therapies, each chapter focuses on a class of targeted chemotherapy agents. The book describes established and evolving diagnostic tests for therapeutic biomarkers that predict benefit, response, resistance, or drug side effects from specific therapeutic interventions. This volume is an essential handbook for health professionals and scientists researching current applicable biomarkers in oncology.
Table of Contents
| Overview: Therapeutic Biomarkers in CancerSherry X. Yang and Janet E. Dancey |
| Statistical Considerations in the Development and Evaluation of Therapeutic Biomarkers in CancerLisa M. McShane and Edward L. Korn and Boris Freidlin |
| Role of Biomarkers in Clinical Development of New Cancer TherapiesHelen X. Chen |
| HER2 as a Prognostic and Predictive Biomarker in CancerSuparna Wedam and Stan Lipkowitz |
| Hormone Receptors and Endocrine Therapy in Breast CancerChia C. Portera and Sherry X. Yang |
| Predictive Biomarkers for Epidermal Growth Factor Receptor (EGFR) Agents in Non-Small Cell Lung CancerJohn Hilton and Penelope A. Bradbury and Janet E. Dancey |
| Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal CancerJose G. Monzon and Janet E. Dancey |
| Targeting BCR-ABL for Molecular Therapy of Chronic Myelogenous LeukemiaShamudheen Rafiyath and Guoqing Wei and Delong Liu |
| Gastrointestinal Stromal Tumors (GISTs): From Molecular Pathogenesis to TherapyJoaquina Baranda and Rashna Madan and Andrew K. Godwin |
| PML/RARa Fusion Gene and Response to Retinoic Acid and Arsenic Trioxide TreatmentAlicja Gruszka and Myriam Alcalay |
| Dihydropyrimidine Dehydrogenase Deficiency and 5-Fluouracil ToxicityEva Gross and AndrÃ(c) B. P. van Kuilenburg |
| UGT1A1 Polymorphisms and Mutations Lead to Irinotecan-Induced ToxicityKellie Reece and William D. Figg |
| The 21-Gene Recurrence Score and Benefit of Chemotherapy in Estrogen Receptor-Positive Breast CancerPetra Rietchel and Joseph A. Sparano |
| MammaPrint for Individualized Recurrence Risk Assessment and Treatment Recommendations for Early-Stage Breast Cancer PatientsSonal J. Desai and Tianhong Li |
| BRCA mutation and PARP InhibitorsMarcie K. Weil and Shivaani Kummar and James H. Doroshow and Alice P. Chen |
| EML4-ALK Fusion Gene and Therapy with ALK-targeted Agents in Non-Small Cell Lung CancerVimal Patel, MD and Biren Saraiya |
| BRAF-Targeted Therapy in Metastatic MelanomaNoori Kim and April C. Deng |
